Uploaded March 2025 | Updated September 2026, 2 days ago
At PNI’s Treatment & Research In Psychedelics (TRIP) Program, we conduct clinical trails at the forefront of innovative and transformative medicine. TRIP, spearheaded by Daniel Kelly, MD and Keith Heinzerling, MD, explores the effect of psychedelic-assisted therapy in treating conditions such as anxiety, depression, and addiction. Our wraparound program includes preparation and integration talk therapy along with one or a few doses of medicine in a safe, nurturing, clinical setting. We are finding that people experience epiphanies and long-lasting breakthroughs, which could otherwise have taken years to achieve through conventional talk therapy and daily medicine. Our larger medical community still does not understand the mechanisms of why this methodology is so sustainable.
Our aim is to bring these powerful treatments into mainstream medicine by achieving FDA approval.
At PNI’s Treatment & Research In Psychedelics (TRIP) Program, we conduct clinical trails at the forefront of innovative and transformative medicine. TRIP, spearheaded by Daniel Kelly, MD and Keith Heinzerling, MD, explores the effect of psychedelic-assisted therapy in treating conditions such as anxiety, depression, and addiction. Our wraparound program includes preparation and integration talk therapy along with one or a few doses of medicine in a safe, nurturing, clinical setting. We are finding that people experience epiphanies and long-lasting breakthroughs, which could otherwise have taken years to achieve through conventional talk therapy and daily medicine. Our larger medical community still does not understand the mechanisms of why this methodology is so sustainable.
Our aim is to bring these powerful treatments into mainstream medicine by achieving FDA approval.
